Hoffmann-La Roche

Roche Hosts Annual Children's Walk to Benefit Local, Underprivileged Youth

Retrieved on: 
Tuesday, May 10, 2022

INDIANAPOLIS, May 10, 2022 /PRNewswire/ -- In celebration of its 125th anniversary, today Roche Diagnostics employees across the U.S. (Indianapolis; Tucson, AZ; Branchburg, NJ; Boston, MA, Carlsbad, CA and San Jose, CA) will participate in the annual Roche Children's Walk, which is aimed at improving the lives of children in our local communities and across the globe. Roche employees in Indianapolis are raising funds for Camp Tataya Mato (part of Jameson Camp), for kids whose lives are impacted by HIV/AIDS. Kids attending the camp come from low-income families and depend on financial assistance.

Key Points: 
  • The Roche Indianapolis location is one of 182 Roche sites in more than 83 countries participating in the Children's Walk, benefiting kids in their local communities and in other developing countries.
  • Roche employees participating in the walk will be joined this year by Andr Hoffmann and Jrg Duschmal, both Roche family representatives and members of the Roche board of directors, who are visiting Indianapolis as part of Roche's 125th anniversary.
  • "Roche is proud to continue this important annual tradition that benefits children locally and around the world," said Matt Sause, president and CEO of Roche Diagnostics North America.
  • Since the first company walk in 2003, more than 274,000 Roche employees have raised CHF 21 million in donations.

AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications

Retrieved on: 
Tuesday, May 10, 2022

This partnership represents a very important milestone as we expand into new indications for the clinical development of AUM001 and realize the full potential of AUM001.

Key Points: 
  • This partnership represents a very important milestone as we expand into new indications for the clinical development of AUM001 and realize the full potential of AUM001.
  • This is part of our commitment to conduct a broad clinical development program to evaluate AUM001 to address unmet medical needs in various solid tumor indications, said Vishal Doshi, CEO of AUM Biosciences.
  • As a monotherapy, AUM001 demonstrated excellent safety, tolerability, and target engagement in two Phase 1 studies.
  • AUM Biosciences is a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology therapies.

NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer

Retrieved on: 
Tuesday, May 10, 2022

Dr. Quiroz brings twenty years of drug development experience in academia and the pharmaceutical and biotechnology industries.

Key Points: 
  • Dr. Quiroz brings twenty years of drug development experience in academia and the pharmaceutical and biotechnology industries.
  • Dr Jorge A. Quiroz, newly appointed Chief Medical Officer at NMD Pharma, said: It is a great time to be joining NMD Pharma as it concludes its Phase IIa study of NMD670 in myasthenia gravis patients and progresses parallel programs based on the novel and exciting science of ClC-1 inhibition.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: Jorge brings years of experience leading clinical teams and programs, and I am pleased that he is joining NMD Pharma at such a pivotal time.
  • In his new role, Dr Quiroz will be based near Boston, Massachusetts where NMD Pharma has recently expanded its presence.

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

Retrieved on: 
Monday, May 9, 2022

LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS.

Key Points: 
  • Dr. Michael Rafii commented: The data published today in JAMA Neurology demonstrate that interventional clinical trials can be successfully conducted in individuals with Down syndrome.
  • Importantly, the ACI-24 anti-Abeta vaccine was safe, well-tolerated and an anti-Abeta immune response was observed in ACI-24-treated but not placebo-treated participants.
  • Rafii MS et al, Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome, A Phase 1b Randomized Clinical Trial, JAMA Neurology, 2022 May 9:79(5).
  • This randomized, double-blind, placebo-controlled, dose-escalation, phase 1b multi-center study reported in JAMA Neurology included 16 adults, aged 25-41 years.

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Retrieved on: 
Friday, May 6, 2022

and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ --Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment of Alexander A. Zukiwski, MD, to the Company's Scientific Advisory Board.

Key Points: 
  • and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ --Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment of Alexander A. Zukiwski, MD, to the Company's Scientific Advisory Board.
  • Prior to Arno in 2007, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune.
  • Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD)and Ortho Biotech.
  • "We're pleased to welcome Dr. Zukiwski to our Scientific Advisory Board," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

Retrieved on: 
Thursday, May 5, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2022 financial and operating results on Thursday, May 12, 2022, following the close of the U.S. financial markets.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2022 financial and operating results on Thursday, May 12, 2022, following the close of the U.S. financial markets.
  • Lineage management will also host a conference call and webcast on Thursday, May 12, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2022 financial and operating results and to provide a business update.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022

Retrieved on: 
Thursday, May 5, 2022

ET to discuss operational and financial results for the first quarter ended March 31, 2022.

Key Points: 
  • ET to discuss operational and financial results for the first quarter ended March 31, 2022.
  • To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13727955.
  • The live webcast will be accessible on the Investors section of Matinas website, www.matinasbiopharma.com , and archived for 90 days.
  • Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Tuesday, May 3, 2022

RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech , a member of the Roche Group.

Key Points: 
  • RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech , a member of the Roche Group.
  • The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC by a group of 73 ophthalmologists.
  • OpRegen is a retinal pigment epithelial cell therapy in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
  • Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterized by severe loss of visual function.

Seagen Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, April 28, 2022

Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022.

Key Points: 
  • Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022.
  • Seagen delivered strong results for the first quarter of 2022 with net product sales increasing 27 percent over the first quarter of 2021, reflecting growth across our portfolio of four approved products, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen.
  • Seagen continues to be well-positioned with significant resources and an expanded geographic footprint to continue executing upon our strategy.
  • The first target under the collaboration has been designated and an undisclosed payment was received in the first quarter of 2022.

Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022

Retrieved on: 
Thursday, April 28, 2022

Management will host a conference call on the same day at 4:30 pm ET.

Key Points: 
  • Management will host a conference call on the same day at 4:30 pm ET.
  • To access the live conference call, please dial (888) 346-6389 fromthe United Statesor (412) 317- 5252 from other locations, shortly before4:30 pm ET.
  • The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section.
  • A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.